Hibsago: FDA Approves Hepatitis B Treatment That May Help Some Patients Stop Medication

For many people living with hepatitis B, medicine is not a short course.

Most people who start it must keep taking it for life, according to the World Health Organization.

A new injection approved in the United States now gives some patients a chance to stop all their hepatitis B medicine and still keep the virus under control.

The United States Food and Drug Administration, the government agency that decides which medicines can be sold in America, approved the injection on 20 October 2026.

It is called Hibsago, and the approval went to GSK, the British drug company behind it.

The news is real, but so are its limits.

Hibsago is not a guaranteed or permanent cure, it is not for everyone, and it comes with serious warnings.

Why hepatitis B treatment often lasts a lifetime

Hepatitis B is a virus that settles in the liver.

Most people do not feel sick when they first catch it, the World Health Organization says, so many never know they have it.

Over the years, the FDA said, the infection can scar the liver and raise the risk of liver cancer.

The World Health Organization estimates that 240 million people were living with long-term hepatitis B in 2024, and 64 million of them were in its African Region.

The medicines that keep the virus low have to be taken for life by most people who start them.

That is why this approval stands out.

How the injection works

In the trials, Hibsago was injected under the skin for up to 24 weeks, about six months, while patients kept taking their usual hepatitis B medicine.

They then stayed on that usual medicine for at least 24 more weeks.

Only after that could some of them stop, and only if their health checks and blood tests met strict conditions.

The drug blocks the instructions the virus uses to make copies of itself, which lowers the amount of virus in the body.

Wendy Carter, a doctor who is acting director of the Office of Infectious Diseases at the FDA's Center for Drug Evaluation and Research, called the approval "an important advance for people living with this serious disease."

One in five

Researchers tested Hibsago in two trials, where some patients received the drug and others received a dummy injection with no medicine in it.

About 24 in every 100 patients on Hibsago met the conditions to stop their usual medicine.

Among those given the dummy injection, none did.

Six months after stopping all hepatitis B treatment, 19 in every 100 patients who had received Hibsago still had the virus under control, and a marker of the infection could not be found in their blood, the FDA said.

That is about one in five, which also means about four in five did not reach that point.

The trials were reported in the New England Journal of Medicine in May 2026 and involved about 1,800 adults.

GSK paid for the research.

The FDA announcement does not say how long the control lasts beyond those six months.

What it costs the body

The medicine carries the FDA's most serious type of warning on its label, for serious liver reactions and for low counts of the blood cells that help blood clot, which can lead to dangerous bleeding.

The FDA also warned about worsening kidney function, serious inflammatory reactions, and serious risks if the injection is not given properly.

The most common side effects were pain or redness where the needle went in, fever, tiredness and headache.

In the trials, about 7 in every 100 patients on Hibsago had a serious side effect, compared with about 4 in every 100 on the dummy injection.

Patients need regular blood tests before and during treatment so doctors can catch problems early.

Who gets to use it

The approval covers only certain adults.

They must not have scarring of the liver, must already have taken hepatitis B medicine for at least six months, and must have the virus already kept low in their blood.

A marker of the infection in their blood must also be at or below a set level, measured with an FDA-approved test.

The FDA also approved a specific lab test, made by the company Roche, to help choose patients and follow them during treatment.

This means a person who has not yet started hepatitis B medicine does not qualify yet, and neither does a person whose liver is already scarred.

A long road to the village clinic

Hibsago is approved in the United States.

Japan approved it first, in August 2026, according to reports by Pharmaceutical Technology and the Indian Pharma Post, and a review is under way in Europe.

GSK has announced approvals in Japan and a regulatory review in Europe, but the company has not provided an African availability timeline in the announcements cited here.

The larger gap is shown in the World Health Organization's worldwide figures.

In 2024, only 65 million people, about 27 in every 100 living with hepatitis B, knew they had it, and only 10 million were on treatment.

That is about 4 in every 100.

A drug that needs a specific blood test, and regular blood checks during treatment, also depends on laboratories being within reach.

The World Health Organization also says a hepatitis B vaccine, usually given soon after birth, gives nearly 100 per cent protection against the virus.

For now, Hibsago is a promising option for a small group of patients, and it shows that stopping hepatitis B medicine is possible for some, though not most.

Whether it ever reaches a clinic far from a big city depends on decisions that have not yet been announced.

Sources:FDA news release, 20 October 2026; World Health Organization, Hepatitis B fact sheet, 28 July 2026; Hou J, et al. N Engl J Med. 2026;394(24):2395-2406. doi:10.1056/NEJMoa2515131; Pharmaceutical Technology, August 2026.